Scarica l'app Stockscreener
3.62
3.21%
-0.12
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABCL Giù?
Forum
Previsione
Precedente Chiudi:
$3.74
Aprire:
$3.73
Volume 24 ore:
2.63M
Relative Volume:
0.53
Capitalizzazione di mercato:
$1.08B
Reddito:
$38.03M
Utile/perdita netta:
$-146.40M
Rapporto P/E:
-6.9615
EPS:
-0.52
Flusso di cassa netto:
$-121.38M
1 W Prestazione:
+1.69%
1M Prestazione:
-8.82%
6M Prestazione:
+14.92%
1 anno Prestazione:
+22.71%
Intervallo 1D:
$3.61
$3.86
Intervallo di 1 settimana:
$3.51
$3.86
Portata 52W:
$1.8906
$6.515
Abcellera Biologics Inc Stock (ABCL) Company Profile
Nome
Abcellera Biologics Inc
Settore
Industria
Telefono
(604) 559-9005
Indirizzo
150 W 4TH AVENUE, VANCOUVER
Confronta ABCL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
3.62 | 1.12B | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-07-07 | Ripresa | Leerink Partners | Outperform |
| 2024-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2024-02-22 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-12-05 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-10-13 | Ripresa | Piper Sandler | Overweight |
| 2023-02-28 | Iniziato | Cowen | Outperform |
| 2022-12-15 | Iniziato | Goldman | Buy |
| 2022-11-16 | Iniziato | Truist | Buy |
| 2021-12-21 | Iniziato | The Benchmark Company | Buy |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-01-05 | Iniziato | BMO Capital Markets | Outperform |
| 2021-01-05 | Iniziato | Berenberg | Buy |
| 2021-01-05 | Iniziato | Credit Suisse | Outperform |
| 2021-01-05 | Iniziato | SVB Leerink | Outperform |
| 2021-01-05 | Iniziato | Stifel | Buy |
Mostra tutto
Abcellera Biologics Inc Borsa (ABCL) Ultime notizie
AbCellera Appoints Dr. Stephen Quake to Board - MSN
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - BioSpace
AbCellera Biologics’ Earnings Call: Key Insights - MSN
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Nasdaq Today Biotech Pioneer - Kalkine Media
AbCellera Biologics Inc (ABCL) Down 23% Since Q3 2025 Results - Finviz
Published on: 2025-12-04 02:33:18 - Newser
ABCL: Advancing a differentiated internal pipeline with strong capital support and end-to-end integration - TradingView
Can AbCellera Biologics Inc. (8QQ) stock resist broad market declines2025 Momentum Check & Safe Capital Preservation Plans - Newser
What dividend safety rating applies to AbCellera Biologics Inc. (8QQ) stock2025 Trade Ideas & Fast Gain Stock Tips - Newser
What makes AbCellera Biologics Inc. (8QQ) stock appealing to growth investorsPortfolio Growth Summary & Accurate Entry and Exit Point Alerts - Newser
9 Best Up and Coming Canadian Stocks to Buy - Insider Monkey
AbCellera Biologics Inc. (ABCL) Approved to Begin ABCL575 Trial for Atopic Dermatitis - MSN
Will AbCellera Biologics Inc. stock benefit from sector rotationJuly 2025 Short Interest & Breakout Confirmation Trade Signals - Newser
Published on: 2025-11-29 10:31:39 - earlytimes.in
AbCellera Biologics to change independent auditor after 2025 annual report By Investing.com - Investing.com Nigeria
AbCellera Biologics to change independent auditor after 2025 annual report - Investing.com
Insider Spends US$178k Buying More Shares In AbCellera Biologics - Yahoo Finance
Why AbCellera Biologics Inc. stock could rally in 2025July 2025 Final Week & Weekly Breakout Watchlists - BỘ NỘI VỤ
AbCellera biologics director Montalbano buys $178k in shares By Investing.com - Investing.com Nigeria
AbCellera biologics director Montalbano buys $178k in shares - Investing.com
AbCellera Biologics Inc. (ABCL) is a Buy at Stifel Nicolaus despite Wider Q3 Net Loss - Insider Monkey
13 Best Canadian Penny Stocks to Buy Right Now - Insider Monkey
AbCellera Biologics Inc. (ABCL) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
How AbCellera Biologics Inc. (8QQ) stock correlates with oil marketsJuly 2025 Price Swings & Expert Curated Trade Setups - newser.com
Is AbCellera Biologics Inc. (8QQ) stock safe for risk averse investors2025 Fundamental Recap & AI Driven Stock Reports - newser.com
How AbCellera Biologics Inc. (8QQ) stock compares with market leadersJuly 2025 Pullbacks & Verified Momentum Stock Watchlist - newser.com
Will AbCellera Biologics Inc. (8QQ) stock outperform energy sector in 2025Market Trend Summary & High Conviction Buy Zone Alerts - newser.com
How AbCellera Biologics Inc. (8QQ) stock reacts to weak economy2025 Trading Volume Trends & Safe Entry Zone Identification - newser.com
Is AbCellera Biologics Inc. (8QQ) stock at risk of policy regulationJobs Report & Daily Entry Point Alerts - newser.com
How AbCellera Biologics Inc. stock reacts to Fed rate cutsAnalyst Upgrade & Expert Curated Trade Setups - newser.com
Is a relief rally coming for AbCellera Biologics Inc. holdersDollar Strength & Fast Gain Stock Trading Tips - newser.com
What’s next for AbCellera Biologics Inc. stock priceQuarterly Investment Review & Capital Efficient Trade Techniques - newser.com
Abcellera Biologics Inc Azioni (ABCL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):